The Technical Analyst
Revance Therapeutics Inc [RVNC]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Revance Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
5.69% $14.67
Last updated: 16 May 2022 @ 11:23 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 067.51 mill |
| EPS: | -4.17 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 72.77 mill |
| Avg Daily Volume: | 0.686 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$16.31 (11.17%) $1.639 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $1.232 ( +/- 8.88%) Range: 12.65 - 15.11 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-04 | Kolaja Carey Oconnor | Buy | 11 343 | Stock Option (Right to buy) |
| 2022-05-04 | Kolaja Carey Oconnor | Buy | 6 059 | Common Stock |
| 2022-05-04 | Nolet Chris | Buy | 11 343 | Stock Option (Right to buy) |
| 2022-05-04 | Nolet Chris | Buy | 6 059 | Common Stock |
| 2022-05-04 | Vickers Philip J. | Buy | 11 343 | Stock Option (Right to buy) |
| INSIDER POWER |
|---|
| 52.93 |
| Last 100 transactions |
| Buy: 1 097 187 | Sell: 445 490 |
Forecast:
13:02 - $14.81
Live Trading Signals (every 1 min)
Forecast
1: 11:32 - $14.71
Forecast 2: 12:22 - $14.68
Forecast 3: 13:02 - $14.81
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.67 (5.69% ) |
| Volume | 0.255 mill |
| Avg. Vol. | 0.686 mill |
| % of Avg. Vol | 37.13 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RVNC
154 Signals | Accuracy: 24.03% | Accuracy Buy: 19.48% | Accuracy Sell: 28.57%
Avg return buy: 0.08 % | Avg return sell: -0.35 %
$1 invested is now $1.05 or 5.18% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 11:11 | buy | $14.71 | $14.67 @ May 16 - 11:22 | -0.27% |
|---|---|---|---|---|
| May 16 - 11:03 | sell | $14.63 | $14.71 @ May 16 - 11:10 | 0.58% |
| May 16 - 10:58 | buy | $14.73 | $14.61 @ May 16 - 11:02 | -0.81% |
| May 16 - 10:54 | sell | $14.61 | $14.73 @ May 16 - 10:58 | 0.83% |
| May 16 - 09:35 | buy | $14.24 | $14.61 @ May 16 - 10:53 | 2.60% |
| May 13 - 15:46 | sell | $13.94 | $14.22 @ May 16 - 09:34 | 2.03% |
| May 13 - 15:42 | buy | $14.00 | $13.95 @ May 13 - 15:45 | -0.36% |
| May 13 - 15:37 | sell | $13.94 | $14.00 @ May 13 - 15:41 | 0.43% |
| May 13 - 15:23 | buy | $13.97 | $13.95 @ May 13 - 15:36 | -0.14% |
| May 13 - 15:20 | sell | $13.92 | $13.95 @ May 13 - 15:22 | 0.22% |
RVNC
Latest Press Releases
2022-05-10 16:05:00 - Press Release
Revance Reports First Quarter 2022 Financial Results, Provides Corporate Update
Nashville, tenn.--(business wire)--revance reports first quarter 2022 financial results, provides corporate update
2022-02-08 12:05:00 - Press Release
Deadline Today Alert: The Schall Law Firm Encourages Investors In Revance Therapeutics, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles, california--(newsfile corp. - february 8, 2022) - the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against revance therapeutics, inc. ("revance" or "the company") (nasdaq: rvnc) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission.
2022-02-08 11:10:00 - Press Release
Rvnc Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Revance Therapeutics, Inc. Investors With Losses To Secure Counsel Before Important February 8 Deadline In Securities Class Action - Rvnc
New york, new york--(newsfile corp. - february 8, 2022) - why: rosen law firm, a global investor rights law firm, reminds purchasers of the securities of revance therapeutics, inc. (nasdaq: rvnc) between november 25, 2019 and october 11, 2021, inclusive (the "class period"), of the important february 8, 2022 lead plaintiff deadline.so what: if you purchased revance securities during the class period you may be entitled to compensation without payment of any out of pocket...
2022-02-08 10:00:00 - Press Release
Rvnc Shareholder Alert: Bronstein, Gewirtz & Grossman, Llc Notifies Revance Therapeutics, Inc. Investors Of Class Action And Lead Plaintiff Deadline: February 8, 2022
New york, new york--(newsfile corp. - february 8, 2022) - bronstein, gewirtz & grossman, llc notifies investors that a class action lawsuit has been filed against revance therapeutics, inc. ("revance" or the "company") (nasdaq: rvnc) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired revance securities between november 25, 2019 and october 11, 2021, inclusive (the "class period"). such investors are encouraged to join this case by visiting the firm's...
2022-02-08 06:00:00 - Press Release
Rvnc Alert: The Klein Law Firm Announces A Lead Plaintiff Deadline Today In The Class Action Filed On Behalf Of Revance Therapeutics, Inc. Shareholders
New york, feb. 8, 2022 /prnewswire/ -- the klein law firm announces that a class action complaint has been filed on behalf of shareholders of revance therapeutics, inc. (nasdaq: rvnc) alleging that the company violated federal securities laws. class period: november 25, 2019 to october 11, 2021 lead plaintiff deadline: february 8, 2022 no obligation or cost to you.
Latest News
2022-05-10 23:00:04 - Seeking Alpha
Revance Therapeutics's (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jessica Serra – Head-Investor Relations and ESG Mark Foley – Chief Executive Officer Dustin Sjuts – President Toby Schilke – Chief Financial Officer Conference Call Participants Ken Cacciatore – Cowen and Co Seamus Fernandez – Guggenheim David Amsellem – Piper Sander Annabel Samimy – Stifel Balaji Prasad – Barclays Vamil Divan – Mizuho Securities Douglas Tsao – H.C. Wainwright Rohit Bhasin – Needham Operator Welcome to the Revance Therapeutics' First Quarter 2022 Financial Results and Corporate Update Conference Call.
2022-05-10 18:49:06 - Zacks Investment Research
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-22 12:08:49 - Stockmarketcom
3 Top Biotech Stocks To Watch This Week
2022-03-22 06:47:05 - Zacks Investment Research
Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?
Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2022-02-21 16:11:14 - Zacks Investment Research
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2021-11-19 08:00:00 - Business Wire
Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at the 2021 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting
NASHVILLE--(BUSINESS WIRE)--Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at 2021 ASDS Annual Meeting
2021-11-10 08:54:10 - Seeking Alpha
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2021 Results - Earnings Call Transcript
Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2021 Results - Earnings Call Transcript
2021-11-09 18:19:04 - Zacks Investment Research
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue Estimates
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 4.35% and -1.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-11-08 10:01:05 - Zacks Investment Research
Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings?
Revance Therapeutics (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
2021-10-29 15:58:42 - Seeking Alpha
Revance Therapeutics: Repricing Shares After A CRL
I've been very bullish on Revance Therapeutics' novel long acting neuromodulator since December 2019.